Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON):...

Area of Science:

• Oncology
• Radiation Oncology
• Hematologic Malignancies

Background:

• Indolent non-Hodgkin's lymphomas (iNHL), such as follicular and marginal zone lymphomas, are sensitive to radiation therapy (RT).
• Standard RT doses (24 Gy) offer good disease control but can cause toxicity.
• Previous attempts at dose reduction (4 Gy) showed inferior outcomes, necessitating further investigation into optimal dosing.

Purpose of the Study:

• To evaluate if reduced-dose hypofractionated RT can achieve comparable disease control to standard RT in iNHL.
• To minimize treatment toxicity and burden for patients with iNHL.
• To compare acute toxicity, quality of life, and treatment outcomes between standard and reduced RT doses.

Main Methods:

• Phase 2 randomized trial comparing two arms: experimental (8-10 Gy in 2-5 fractions) and standard of care (24 Gy in 12 fractions).
• Randomization of patients 1:1 to receive either experimental or standard RT.
• Primary endpoint: acute toxicity (grade ≥ 2). Secondary endpoints include quality of life, response rates, local control, and survival.

Main Results:

• This section will be populated once the trial results are available.
• The study is designed to detect differences in acute toxicity and disease control.
• Exploratory analyses will examine financial toxicity, healthcare costs, late toxicity, and prognostic biomarkers.

Conclusions:

• The study aims to establish a less toxic and burdensome RT regimen for iNHL.
• Findings will inform optimal radiation dosing strategies for indolent lymphomas.
• Potential to improve patient-reported outcomes and reduce healthcare expenditure.